Starjemza's inclusion in Cost Plus Drugs' portfolio aims to challenge traditional specialty medication economics and enhance ...
Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) today announced the addition of Starjemza®, a new biosimilar medication, to its growing portfolio of affordable prescription drugs. Starjemza® ...
Mark Cuban Cost Plus adds Stelara biosimilar Starjemza, offering it at $360 per syringe to lower biologic drug costs for patients.
On November 6, 2025, Hikma Pharmaceuticals PLC, and its subsidiary Hikma Pharmaceuticals USA Inc., announced the launch of ...
(RTTNews) - Bio-Thera Solutions Ltd and Hikma Pharmaceuticals PLC announced that the U.S. Food and Drug Administration has approved STARJEMZA (ustekinumab-hmny) Injection, a biosimilar referencing ...
Phase 3 trial results showed comparable efficacy between the biosimilar and the reference product. The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to ...
Bio-Thera and Hikma entered into a license and commercialization agreement for STARJEMZA ® in August 2021. Under the terms of the agreement, Bio-Thera is responsible for the development and ...
Ustekinumab offers superior itch relief compared to guselkumab in severe psoriasis, despite guselkumab's better skin lesion improvement. The study involved 108 patients, with 90.4% of ...
GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback